Recent News
Read ArticleThe last day in London was exciting as both the Late-Breaking abstracts and new EULAR guidelines were presented.
INDIGO: Switching B Cells Off, Not Out, in IgG4-Related Disease
B-cell targeting has moved to the centre of IgG4-related disease treatment, with inebilizumab, a CD19 depleter, as the recent benchmark. At EULAR 2026, INDIGO tested whether the disease can be controlled by switching B cells off rather than depleting them.
Read ArticleRA-ILD in the Age of Treat-to-Target: Put the Probe on the Chest
At EULAR 2026, speakers of the session “Catching Your Breath: Unravelling RA Associated Interstitial Lung Disease (ILD)” noted RA-ILD is one of the few outcomes not improving in the biologic era. Three abstracts reinforce that message and make the case for a practical, low-cost screening tool that is already in most rheumatologists’ hands.
Read Article
Links:
Links:
Links:
Links:
Jiha Lee @JihaRheum ( View Tweet)
Links:
Jiha Lee @JihaRheum ( View Tweet)
Links:
Jiha Lee @JihaRheum ( View Tweet)
Jiha Lee @JihaRheum ( View Tweet)
Jiha Lee @JihaRheum ( View Tweet)



Poster Hall
